BIOS Fund III NT, LP insider trades: Actuate Therapeutics (ACTU) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where BIOS Fund III NT, LP reports to the SEC
Open-market buys and sales
20 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 27, 2025 | ACTU | ↑ Buy | 71,428 | $7.00 | $500K | Directly held by Bios 2024 Co-Invest, LP | Jun 30, 2025 (3d) |
| Aug 14, 2024 | ACTU | ↑ Buy | 375,000 | $8.00 | $3.0M | Directly held by Bios Clinical Opportuni | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↑ Buy | 125,000 | $8.00 | $1.0M | Directly held by Bios 2024 Co-Invest, LP | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 17,361 | $9.00 | $156K | Directly held by Bios Fund II QP, LP | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 5,314 | $9.00 | $48K | Directly held by Bios Fund II, LP | Aug 14, 2024 (0d) |
| Aug 14, 2024 | ACTU | ↓ Sell | 2,324 | $9.00 | $21K | Directly held by Bios Fund II NT, LP | Aug 14, 2024 (0d) |
| Jun 21, 2023 | AZTR | ↑ Buy | 456,412 | $5.00 | $2.3M | Directly held by Bios Fund III QP, LP | Jun 23, 2023 (2d) |
| Jun 21, 2023 | AZTR | ↑ Buy | 73,708 | $5.00 | $369K | Directly held by Bios Fund III NT, LP | Jun 23, 2023 (2d) |
| Jun 21, 2023 | AZTR | ↑ Buy | 69,880 | $5.00 | $349K | Directly held by Bios Fund III, LP | Jun 23, 2023 (2d) |
| Dec 12, 2022 | INAB | ↑ Buy | 75,001 | $2.48 | $186K | Indirect | Dec 13, 2022 (1d) |
| Nov 28, 2022 | CGTX | ↑ Buy | 12,220 | $2.65 | $32K | By Bios Fund III QP, LP | Nov 29, 2022 (1d) |
| Nov 28, 2022 | CGTX | ↑ Buy | 1,973 | $2.65 | $5K | By Bios Fund III NT, LP | Nov 29, 2022 (1d) |
| Nov 28, 2022 | CGTX | ↑ Buy | 1,871 | $2.65 | $5K | By Bios Fund III, LP | Nov 29, 2022 (1d) |
| Nov 16, 2022 | CGTX | ↑ Buy | 54,009 | $1.40 | $76K | By Bios Fund III QP, LP | Nov 17, 2022 (1d) |
| Nov 16, 2022 | CGTX | ↑ Buy | 8,722 | $1.40 | $12K | By Bios Fund III NT, LP | Nov 17, 2022 (1d) |
| Nov 16, 2022 | CGTX | ↑ Buy | 8,269 | $1.40 | $12K | Bios Fund III, LP | Nov 17, 2022 (1d) |
| Nov 15, 2022 | CGTX | ↑ Buy | 1,141,030 | $1.20 | $1.4M | By Bios Fund III QP, LP | Nov 16, 2022 (1d) |
| Nov 15, 2022 | CGTX | ↑ Buy | 184,270 | $1.20 | $221K | By Bios Fund III NT, LP | Nov 16, 2022 (1d) |
| Nov 15, 2022 | CGTX | ↑ Buy | 174,700 | $1.20 | $210K | Bios Fund III, LP | Nov 16, 2022 (1d) |
| Sep 28, 2022 | INAB | ↑ Buy | 25,000 | $2.02 | $51K | Indirect | Sep 29, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ACTU insiders
Open-market trades in the last 12 months
About BIOS Fund III NT, LP's insider trades
BIOS Fund III NT, LP is a director at Actuate Therapeutics (ACTU). Since Sep 28, 2022, it has reported 17 open-market purchases worth $9.7M and 3 sales worth $225K on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include grants and awards (7 filings), other transactions (4 filings), conversions (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ACTU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.